![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Polarean Imaging Plc | POLX | London | Ordinary Share |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.875 | 1.825 | 1.90 | 1.825 | 1.875 |
Industry Sector |
---|
PHARMACEUTICALS & BIOTECHNOLOGY |
Top Posts |
---|
Posted at 19/7/2024 17:41 by mr pierrepoint @bones Your assumption that POLX will not be paid for this work has been posted to X as a question. Will update if the company responds. |
Posted at 19/7/2024 13:38 by bones698 Looks like Polx doing that for free as no money mentioned. Not the kind of deals they need to be signing uptake is painfully slow still |
Posted at 19/7/2024 11:09 by fft Errr. POLX are buying the older machines and selling them the newer ones. There is no mention of how much POLX are paying for them, and I suspect it is higher than the price POLX will get when they try and sell them again !This seems like a loss leader to get influential people involved. Note, there is no quote from the Virginia people saying how they always wanted the POLX kit. Indeed, unless I have looked at a wrong version of the RNS there is no quote at all In other words POLX are probably losing money on this deal and if other sites see this they may also like to do a trade in, but the more that do it the worse for POLX cash flow. My 2 cents |
Posted at 17/7/2024 11:16 by the technical trader As requested:A quick comparison of POLX, with recent rocket stock CPX: |
Posted at 16/7/2024 08:43 by kingston78 POLX is on an upward move. It is going to break the 2 p level soon. The low placing price was forced upon the company due to market conditions. In better times it could have raised money at 3 or 4 p when its share price was at 5 p, which dropped like a stone.It has a world-first device used in hospitals in the US. All it needs is to expand the sales network in the US and other countries. Management should capitalise on the company's invention quickly. |
Posted at 11/7/2024 13:32 by john henry There's know doubt POLX are in the right space at the right time. Question is can the present management execute. Jury is out. Up till now 10/10 for development and FDA approval. 3/10 for commercialisation progress. Financials Placing etc big fat Zero. |
Posted at 11/7/2024 08:20 by socionomics Have faith young men. POLX and STX are both ready to pop, just waiting for the catalyst. |
Posted at 05/7/2024 08:01 by moontheloon Stifel re covering polx as a buy |
Posted at 21/6/2024 15:26 by kingston78 Someone who I know was selling a plot of land to another friend for £1 million. It was probably over valued, but that friend was helping him. Anyway, in a reunion function, that friend was saying that he had just sold that plot of land for £10 million to an unconnected party. This is a true story.If you need the money and/or want to make a quick profit you sell POLX, which many people have done. If you want to make mega profit on POLX, you should wait for more corporate actions or positive commercial announcements. |
Posted at 20/6/2024 10:46 by kingston78 I think that the two largest shareholders / backers of the company will, at an opportune time, engineer a bid for POLX by a larger group. They will clobber their shareholdings, together with recommendation by the directors, agree to a sale of the company at an attractive price.Digressing a little, private equity consortium has had their bid offers for Hargreaves Landsdown refused twice. But the directors will agree to a much higher offer of £5.4 billion for HL. The same thing will happen to POLX in my opinion, at 10 p each share when the company has won sufficient number of users for its products. There will be a push for worldwide offering. You just need to look at the historical share chart to see how much the company will claw back in terms of share price. A bid or not, there is a compelling business case for the share price to go higher. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions